United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 2 minute read Pharma Industry News Millendo Therapeutics begins human trial of VMS drug candidate MLE-301 Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301,… bypharmanewsdailySeptember 24, 2020